Lack of Antibiotics Drives Superbug Spread
- MUNICH (IT Boltwise) — Limited access to essential antibiotics in low- and middle-income countries is significantly exacerbating the spread of drug-resistant infections, according to a recent study.The research,...
- The study highlights a critical disparity in access to life-saving medications, contributing to increased suffering, death, and the rise of antimicrobial resistance (AMR), a growing threat to global...
- Experts warn that AMR, where bacteria and other pathogens develop resistance to commonly used treatments, could lead to an estimated 1.9 million deaths annually by 2050.
Antibiotic Access Gap Fuels Drug Resistance, Study Finds
Table of Contents
- Antibiotic Access Gap Fuels Drug Resistance, Study Finds
- Antibiotic Access Gap: Your Questions Answered
- What is the main issue highlighted in the study?
- What is antimicrobial resistance (AMR)?
- Why is AMR a growing threat?
- What are the potential consequences of AMR?
- How does lack of antibiotic access contribute to AMR?
- What percentage of people with severe, medication-resistant infections receive necessary antibiotics?
- Which countries where included in the study?
- What types of infections were analyzed in the study?
- What were the key findings regarding antibiotic availability in the studied countries?
- What were the ranges of antibiotic availability?
- What is the treatment gap?
- What are the barriers to accessing antibiotics?
- How does the study propose addressing the antibiotic access gap?
- what is the goal in terms of patients receiving treatment of AMR?
- What is the “supply cascade”?
- Summarizing Antibiotic Availability & Outcomes in 2019
- Why is urgent action needed?
MUNICH (IT Boltwise) — Limited access to essential antibiotics in low- and middle-income countries is significantly exacerbating the spread of drug-resistant infections, according to a recent study.The research, published in The Lancet Infectious Diseases, reveals that fewer than 7% of individuals with severe, medication-resistant infections receive the necessary antibiotics.
Alarming Treatment Shortfall
The study highlights a critical disparity in access to life-saving medications, contributing to increased suffering, death, and the rise of antimicrobial resistance (AMR), a growing threat to global health.Researchers are calling for immediate action, drawing parallels to the global effort to provide HIV medication to affected populations in Africa.
AMR Threat Looms Large
Experts warn that AMR, where bacteria and other pathogens develop resistance to commonly used treatments, could lead to an estimated 1.9 million deaths annually by 2050. While overuse of antibiotics is a known driver of resistance, the study emphasizes that inadequate access to these medications is a severely neglected aspect of the problem.
Quantifying the Treatment Gap
The research, spearheaded by the Global Antibiotic research and Advancement Partnership (GARDP), is the first to quantify the treatment gap in low- and middle-income countries. the study focused on Bangladesh, Brazil, Egypt, India, Kenya, Mexico, Pakistan, and South Africa, utilizing modeling data to assess the prevalence of carbapenem-resistant gram-negative (CRGN) infections, which are increasingly resistant to multiple drugs.
Stark disparities Revealed
In 2019, the eight countries examined recorded an estimated 1.5 million CRGN infections and nearly 480,000 deaths. despite this, only approximately 104,000 courses of antibiotics effective against CRGNs were procured. on average, appropriate antibiotics were available in just 6.9% of cases, ranging from a low of 0.2% in Kenya to a high of 14.9% in Mexico and Egypt.
Dr. Jennifer Cohn, GARDP’s Global Access Manager, suggests this pattern likely extends to other resource-limited nations. The infections analyzed included pneumonia, bloodstream infections, and intricate urinary tract infections. She emphasized that the lack of medication not only increases illness and death but also fuels the spread of AMR.
Barriers to Access
Cohn identifies several factors contributing to the treatment gap. These include patients being unable to reach hospitals for diagnosis or being unable to afford treatment once diagnosed. She also notes that the focus on introducing newer antibiotics in the U.S. and some European countries overlooks the regions bearing the greatest burden of infection.
Drawing Parallels to HIV Response
Cohn suggests that accomplished strategies employed in addressing HIV could be adapted for AMR. GARDP is collaborating with the pharmaceutical company Shionogi to accelerate global access to Cefiderocol, an antibiotic effective against some resistant infections, through voluntary licensing.
Call for Ambitious Goals
the research team advocates for treatment goals similar to the “supply cascade” established by global HIV initiatives, aiming for at least 95% of people with HIV diagnosed, 95% treated, and 95% virally suppressed by 2030.
Urgent Action Needed
Professor Alison Holmes of the University of Liverpool, who leads the global network for antimicrobial optimization, stresses that the study should prompt “immediate measures.” She warns that failure to address these critical gaps in access and care will exacerbate the burden of AMR, leading to more preventable deaths, poorer patient outcomes, and an already devastating global health crisis spiraling further out of control.
For additions and information, contact the editorial team at DE-Info[at]it-boltwise.de. In the event of AI-generated news and content, we ask that you contact us regarding any false information or misinformation.
Antibiotic Access Gap: Your Questions Answered
What is the main issue highlighted in the study?
The study focuses on the significant problem of limited access to essential antibiotics in low- and middle-income countries, and how this is accelerating the spread of drug-resistant infections.
What is antimicrobial resistance (AMR)?
Antimicrobial resistance (AMR) occurs when bacteria and other pathogens develop resistance to medications like antibiotics, making infections harder to treat.
Why is AMR a growing threat?
AMR poses a significant threat because it renders common treatments ineffective, leading to increased suffering, death, and the potential for a global health crisis.
What are the potential consequences of AMR?
Experts warn that AMR could lead to an estimated 1.9 million deaths annually by 2050.This is primarily due to the ineffectiveness of antibiotics in treating infections.
How does lack of antibiotic access contribute to AMR?
The study emphasizes that inadequate access to antibiotics is a severely neglected aspect of the AMR problem. Without proper access, infections are not treated effectively, which can lead to drug-resistant strains.
What percentage of people with severe, medication-resistant infections receive necessary antibiotics?
The study reveals that fewer than 7% of individuals with severe, medication-resistant infections receive the required antibiotics.
Which countries where included in the study?
The study, spearheaded by the Global Antibiotic research and Advancement Partnership (GARDP), focused on:
- Bangladesh
- brazil
- Egypt
- india
- Kenya
- Mexico
- Pakistan
- South Africa
What types of infections were analyzed in the study?
The study specifically looked at carbapenem-resistant gram-negative (CRGN) infections, which are increasingly resistant to multiple drugs, including:
- Pneumonia
- Bloodstream infections
- Intricate urinary tract infections
What were the key findings regarding antibiotic availability in the studied countries?
The study found that, on average, appropriate antibiotics were available in just 6.9% of cases across the eight countries examined.
What were the ranges of antibiotic availability?
The availability of appropriate antibiotics varied greatly:
- A low of 0.2% in Kenya
- A high of 14.9% in Mexico and Egypt
What is the treatment gap?
The treatment gap refers to the discrepancy between the need for effective antibiotics and their actual availability in low- and middle-income countries. The study quantified this gap for the first time.
What are the barriers to accessing antibiotics?
Several factors contribute to the treatment gap, including:
- Patients’ inability to reach hospitals for diagnosis.
- Patients’ inability to afford treatment onc diagnosed.
- The focus on introducing newer antibiotics in developed countries,which overlooks the regions with the greatest burden of infection.
How does the study propose addressing the antibiotic access gap?
The study suggests adapting strategies used to address HIV, such as implementing similar treatment goals.These goals include ensuring widespread access to medication and proactive patient management. GARDP is also collaborating with pharmaceutical companies to accelerate access to new antibiotics.
what is the goal in terms of patients receiving treatment of AMR?
The research team advocates for treatment goals similar to HIV initiatives, aiming for:
- At least 95% of people with AMR diagnosed.
- 95% treated.
- 95% virally suppressed by 2030.
What is the “supply cascade”?
The “supply cascade” refers to the structured approach used in global initiatives to address HIV, ensuring diagnosis, treatment, and viral suppression. The research team suggests adapting it to AMR.
Summarizing Antibiotic Availability & Outcomes in 2019
The following table summarizes the available information,based on the article.
| Country | Estimated CRGN Infections (2019) | Estimated Deaths (2019) | Approximate Antibiotic Courses Procured | % cases with Appropriate Antibiotics |
|---|---|---|---|---|
| Study Focused on 8 Countries | 1.5 million | 480,000 | ~104,000 | 6.9% (Average) |
| Kenya | N/A | N/A | N/A | 0.2% |
| Mexico and Egypt | N/A | N/A | N/A | 14.9% |
Why is urgent action needed?
Failure to address these gaps will worsen the AMR burden, leading to more preventable deaths, poorer patient outcomes, and further global health crises.